Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
FHD-286 by Foghorn Therapeutics for Chronic Myelomonocytic Leukemia (CMML): Likelihood of Approval
FHD-286 is under clinical development by Foghorn Therapeutics and currently in Phase I for Chronic Myelomonocytic Leukemia (CMML). According to...
Data Insights
Risk adjusted net present value: What is the current valuation of Foghorn Therapeutics's FHD-286?
FHD-286 is a small molecule commercialized by Foghorn Therapeutics, with a leading Phase I program in Chronic Myelomonocytic Leukemia (CMML)....